Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
Parasites & Vectors
|
September 16, 2021
Contrasting effects of the alkaloid ricinine on the capacity of Anopheles gambiae and Anopheles coluzzii to transmit Plasmodium falciparum
Domonbabele F D S Hien, Prisca S L Paré, Amanda Cooper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2019
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
V Guarneri, M V Dieci, G Bisagni, et al.
Plos Pathogens
|
June 10, 2022
Using an antimalarial in mosquitoes overcomes Anopheles and Plasmodium resistance to malaria control strategies
Douglas G Paton, Alexandra S Probst, Erica Ma, et al.
ESMO Open
|
April 19, 2023
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
F Schettini, O Martínez-Sáez, C Falato, et al.
ESMO Open
|
March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
G Villacampa, T Pascual, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
P Nuciforo, T Pascual, J Cortés, et al.
NPJ Precision Oncology
|
March 20, 2021
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
G Griguolo, G Serna, T Pascual, et al.
ESMO Open
|
September 2, 2025
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
T Pascual, G Villacampa, M Oliveira, et al.
ESMO Open
|
January 18, 2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers
F Lynce, O Martínez-Sáez, B Walbaum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
M Oliveira, C Falato, J M Cejalvo, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
Parasites & Vectors
|
September 16, 2021
Contrasting effects of the alkaloid ricinine on the capacity of Anopheles gambiae and Anopheles coluzzii to transmit Plasmodium falciparum
Domonbabele F D S Hien, Prisca S L Paré, Amanda Cooper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2019
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
V Guarneri, M V Dieci, G Bisagni, et al.
Plos Pathogens
|
June 10, 2022
Using an antimalarial in mosquitoes overcomes Anopheles and Plasmodium resistance to malaria control strategies
Douglas G Paton, Alexandra S Probst, Erica Ma, et al.
ESMO Open
|
April 19, 2023
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
F Schettini, O Martínez-Sáez, C Falato, et al.
ESMO Open
|
March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
G Villacampa, T Pascual, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
P Nuciforo, T Pascual, J Cortés, et al.
NPJ Precision Oncology
|
March 20, 2021
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
G Griguolo, G Serna, T Pascual, et al.
ESMO Open
|
September 2, 2025
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
T Pascual, G Villacampa, M Oliveira, et al.
ESMO Open
|
January 18, 2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers
F Lynce, O Martínez-Sáez, B Walbaum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
M Oliveira, C Falato, J M Cejalvo, et al.
Page
of 4